A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

By Hurwitz Herbert   Cohen Roger   McGovren J.   Hirawat Samit   Petros William   Natsumeda Yutaka   Yoshinari Tomoko  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 139-147

Springer Publishing Company

Access to resources Recommend Favorite

Cell Cycle Effects of the Novel Topoisomerase I Inhibitor NU/ICRF 505 in a Panel of Chinese Hamster Ovary Cell Lines

By Macpherson J.S.   Cummings J.   Meikle I.   Miller E.P.   Smyth J.F.  

European Journal of Cancer, Vol. 33, Iss. 2, 1997-02 ,pp. : 280-283

Elsevier

Access to resources Recommend Favorite

Synergistic interaction between MEK inhibitor and gefitinib in EGFRTKIresistant human lung cancer cells

By            

Oncology Letters, Vol. 10, Iss. 4, 2015-01 ,pp. : 2652-2656

Spandidos Publications

Access to resources Recommend Favorite

An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed

By Graham-Cole Claire   Thomas Huw   Taylor Gordon   Newell David   Melton Roger   Hesp Richard   Boddy Alan  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 2, 2007-02 ,pp. : 197-206

Springer Publishing Company

Access to resources Recommend Favorite

Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer

By            

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 435-441

Spandidos Publications

Access to resources Recommend Favorite